Advertisement
UK markets closed
  • FTSE 100

    8,155.72
    -49.17 (-0.60%)
     
  • FTSE 250

    21,067.68
    -166.48 (-0.78%)
     
  • AIM

    784.13
    -3.54 (-0.45%)
     
  • GBP/EUR

    1.1864
    -0.0011 (-0.09%)
     
  • GBP/USD

    1.2913
    -0.0034 (-0.26%)
     
  • Bitcoin GBP

    51,878.66
    +2,581.99 (+5.24%)
     
  • CMC Crypto 200

    1,383.25
    +52.35 (+3.93%)
     
  • S&P 500

    5,505.00
    -39.59 (-0.71%)
     
  • DOW

    40,287.53
    -377.49 (-0.93%)
     
  • CRUDE OIL

    80.26
    -2.56 (-3.09%)
     
  • GOLD FUTURES

    2,400.70
    -55.70 (-2.27%)
     
  • NIKKEI 225

    40,063.79
    -62.56 (-0.16%)
     
  • HANG SENG

    17,417.68
    -360.73 (-2.03%)
     
  • DAX

    18,171.93
    -182.83 (-1.00%)
     
  • CAC 40

    7,534.52
    -52.03 (-0.69%)
     

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GENFIT S.A.
GENFIT S.A.

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) July 9, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of June 30, 2024:

  • 131,000 shares

  • €700 885.51

During the first half of 2024, total trading was:

  • On the buy side: 1 515,865 shares for a total amount of €5,499,002.56

  • On the sell side: 1 532,677 shares for a total amount of €5,669,272.79

ADVERTISEMENT

During this same period, the number of trades were:

  • On the buy side: 2,256

  • On the sell side: 2,012

As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

  • 27, 911 shares

  • €769 849,43

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, NTZ, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was exemplified in the FDA’s accelerated approval of IQIRVO® (elafibranor1) for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to GENFIT, including, but not limited to statements about GENFIT’s research and development programs. The use of certain words, such as "believe", "potential", "expect", “target”, “may”, “will”, "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, potential commercial success of elafibranor if approved, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2023 Universal Registration Document filed on April 5, 2024 (no. D.24-0246) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr) and the AMF's website (www.amf.org), and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company’s 2023 Annual Report on Form 20-F filed with the SEC on April 5, 2024 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACT

GENFIT | Investors

Tel: +33 3 2016 4000 | investors@genfit.com

PRESS RELATIONS | Media

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

APPENDIX
H1 2024

 

Buy side

Sell-side

Date

Number of executions

Number of shares

Traded amounts in EUR

Number of executions

Number of shares

Traded amounts in EUR

TOTAL

2 256

1 515 865

5 499 002,56

2 012

1 532 677

5 669 272,79

02/01/2024

20

15001

54 728,60

44

67299

246 531,04

03/01/2024

20

24570

92 373,37

33

27528

104 315,70

04/01/2024

27

21790

81 057,27

38

12724

47 598,19

05/01/2024

46

40442

146 853,80

20

8106

29 367,79

08/01/2024

27

26976

94 566,26

26

17813

63 060,34

09/01/2024

37

24367

86 272,58

18

25934

92 719,50

10/01/2024

26

29612

102 891,63

7

8128

28 366,80

11/01/2024

26

18543

63 060,66

11

9887

33 985,77

12/01/2024

11

12166

41 322,79

8

14152

48 363,75

15/01/2024

22

23972

80 216,54

10

5131

17 240,16

16/01/2024

40

28677

94 811,61

14

14428

48 312,01

17/01/2024

116

39086

124 922,76

11

13537

43 114,40

18/01/2024

17

17938

57 074,23

13

15101

48 777,14

19/01/2024

17

8516

26 962,76

6

4965

15 909,25

22/01/2024

23

21001

69 693,29

95

96736

323 324,60

23/01/2024

35

19854

71 395,38

59

43854

157 143,79

24/01/2024

18

20883

76 614,30

36

30883

114 842,76

25/01/2024

29

27704

101 327,66

25

27704

102 086,47

26/01/2024

27

39500

142 628,58

2

2

7,34

29/01/2024

32

17001

61 163,65

23

30200

109 590,97

30/01/2024

22

10488

39 125,59

13

11300

42 502,01

31/01/2024

4

2091

7 707,91

1

1

3,72

01/02/2024

25

25594

92 362,86

7

5429

19 816,01

02/02/2024

18

12001

43 093,55

28

17171

61 917,94

05/02/2024

22

27832

98 386,12

29

18473

65 209,69

06/02/2024

8

6000

21 255,00

40

72699

259 700,76

07/02/2024

26

30739

108 303,64

5

5001

18 103,62

08/02/2024

24

14467

50 178,93

13

18701

65 251,34

09/02/2024

15

14885

51 343,43

7

7945

27 618,09

12/02/2024

52

42657

154 536,50

42

66333

238 579,90

13/02/2024

30

19660

68 994,80

14

4660

16 820,50

14/02/2024

6

5001

17 340,97

3

5001

17 503,50

15/02/2024

16

15002

52 269,52

18

12531

43 910,25

16/02/2024

3

5001

17 828,57

19

11971

42 940,22

19/02/2024

15

10499

37 096,54

6

4450

15 903,01

20/02/2024

21

15170

52 462,26

3

2501

8 778,48

21/02/2024

26

20035

67 418,38

7

3092

10 450,99

22/02/2024

16

12451

41 475,28

20

24141

81 334,65

23/02/2024

7

10031

33 604,35

4

3154

10 723,57

26/02/2024

11

7182

23 630,29

11

7182

23 773,93

27/02/2024

2

2494

8 280,08

4

6752

22 672,27

28/02/2024

16

20037

66 137,33

13

9292

30 539,09

29/02/2024

32

29383

94 700,53

4

4534

14 651,98

01/03/2024

11

9765

30 847,34

16

15863

50 722,42

04/03/2024

16

14225

46 783,46

20

12041

39 944,45

05/03/2024

24

18730

60 015,98

3

2501

8 103,24

06/03/2024

17

7334

23 581,89

5

6907

22 315,34

07/03/2024

29

14223

45 711,30

11

9223

29 820,73

08/03/2024

7

9489

30 243,25

6

5105

16 318,80

11/03/2024

20

10595

33 999,25

16

11247

36 350,64

12/03/2024

7

2316

7 455,46

6

6475

20 981,01

13/03/2024

11

10101

32 563,70

28

18414

60 030,74

14/03/2024

7

8614

27 799,53

7

4902

15 881,55

15/03/2024

25

18874

59 776,03

13

7416

23 517,55

18/03/2024

21

10233

32 463,58

8

12501

39 915,69

19/03/2024

20

13621

44 243,19

29

18210

59 488,06

20/03/2024

19

12925

41 349,14

18

12501

40 390,73

21/03/2024

12

4921

15 840,99

6

3921

12 693,26

22/03/2024

8

3001

9 953,27

17

9425

31 091,10

25/03/2024

2

2501

8 303,35

5

5001

16 728,35

26/03/2024

10

8001

26 583,40

4

2415

8 138,55

27/03/2024

6

4587

15 220,49

8

5001

16 753,30

28/03/2024

8

7915

26 048,66

9

7501

24 990,86

02/04/2024

19

15001

49 115,82

5

2267

7 571,78

03/04/2024

6

5001

16 065,71

5

7501

24 340,75

04/04/2024

14

8181

26 591,69

2

2501

8 178,27

05/04/2024

57

27274

86 585,13

3

3001

9 593,24

08/04/2024

14

6720

21 244,81

28

12493

40 004,46

09/04/2024

10

4323

13 873,59

14

11823

38 395,07

10/04/2024

6

4549

14 692,36

8

3049

9 893,79

11/04/2024

8

4501

14 818,24

16

14005

46 626,71

12/04/2024

10

2501

8 388,35

8

3247

11 027,40

15/04/2024

22

8660

28 376,48

2

2001

6 643,32

16/04/2024

30

10400

33 239,44

10

7651

24 585,80

17/04/2024

11

6459

20 550,02

8

4501

14 350,67

18/04/2024

2

1501

4 758,19

5

3001

9 573,19

19/04/2024

25

4284

13 519,15

4

548

1 726,21

22/04/2024

6

942

2 985,58

10

8646

27 778,91

23/04/2024

11

2500

8 080,00

12

4148

13 477,52

24/04/2024

9

2501

8 030,74

1

1

3,24

25/04/2024

8

3808

12 149,46

1

1

3,21

26/04/2024

2

401

1 267,18

11

1127

3 597,64

29/04/2024

1

1

3,21

9

1875

6 038,76

30/04/2024

11

2295

7 366,54

4

1501

4 878,23

02/05/2024

2

153

489,6

2

272

883,95

03/05/2024

11

1001

3 238,21

8

3480

11 367,45

06/05/2024

4

2030

6 657,20

6

4251

14 050,75

07/05/2024

1

1

3,26

3

2002

6 546,54

08/05/2024

4

1501

5 010,82

27

23822

79 591,21

09/05/2024

3

941

3 158,57

11

4247

14 325,09

10/05/2024

8

2026

6 856,51

29

15855

54 238,53

13/05/2024

12

5776

19 620,84

29

3259

11 351,81

14/05/2024

5

1180

3 984,13

6

1918

6 544,20

15/05/2024

11

2476

8 314,14

29

13980

47 819,99

16/05/2024

1

1

3,47

5

1001

3 465,80

17/05/2024

10

2401

8 291,30

7

6101

21 244,84

20/05/2024

1

1

3,48

64

26344

92 536,99

21/05/2024

7

3589

13 223,49

6

1338

4 940,65

22/05/2024

6

3293

12 137,64

44

18546

72 575,69

23/05/2024

24

8917

36 812,14

29

16372

68 980,48

24/05/2024

7

2370

9 717,24

19

4370

18 355,57

27/05/2024

18

5251

21 839,22

7

3751

15 724,19

28/05/2024

2

501

2 144,20

9

4202

17 978,55

29/05/2024

1

1

4,31

24

18300

83 270,49

30/05/2024

5

1501

8 054,83

24

10501

54 139,80

31/05/2024

34

29001

142 793,38

14

6001

31 625,81

03/06/2024

22

21001

98 104,70

34

35001

168 654,77

04/06/2024

6

6001

29 640,08

24

9001

45 605,10

05/06/2024

33

28453

137 739,27

83

35453

173 952,98

06/06/2024

4

2001

9 604,80

30

24526

120 530,08

07/06/2024

7

5001

24 544,81

36

22476

112 524,30

10/06/2024

12

6001

29 204,95

15

8001

39 714,88

11/06/2024

26

16001

79 795,55

28

16001

80 764,73

12/06/2024

45

26201

120 430,80

24

16627

76 926,15

13/06/2024

65

40001

179 794,49

6

7575

35 330,25

14/06/2024

70

45001

188 049,28

14

21001

86 794,40

17/06/2024

25

15001

56 793,79

11

15001

57 808,75

18/06/2024

11

6501

25 780,30

14

8001

32 584,07

19/06/2024

26

17001

66 196,96

4

6001

23 833,93

20/06/2024

13

4001

14 903,73

12

7501

28 406,21

21/06/2024

38

12001

45 438,91

9

6001

22 783,88

24/06/2024

28

17001

62 773,81

13

8001

29 388,79

25/06/2024

17

9001

33 182,01

14

11001

41 373,66

26/06/2024

16

5001

18 363,72

15

11001

40 491,05

27/06/2024

3

1001

3 688,72

7

4001

14 888,72

28/06/2024

17

9709

34 658,80

6

2709

9 529,88

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com


1  Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark IQIRVO®.

Attachment